IFNL4 ss469415590 variant is associated with treatment response in Japanese HCV genotype 1 infected individuals treated with IFN-including regimens

International Journal of Hepatology

Volumn 2014, Issue , 2014, Pages

  Miyamura, Tatsuo ^a   Kanda, Tatsuo ^a   Nakamoto, Shingo ^a   Arai, Makoto ^a   Nakamura, Masato ^a   Wu, Shuang ^a   Jiang, Xia ^a   Sasaki, Reina ^a   Haga, Yuki ^a   Yasui, Shin ^a   Ooka, Yoshihiko ^a   Chiba, Tetsuhiro ^a   Imazeki, Fumio ^a   Mikami, Shigeru ^b   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Kikkoman General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IFNL4 PROTEIN; PEGINTERFERON; PROTEIN VARIANT; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84963564781     PISSN: 20903448     EISSN: 20903456     Source Type: Journal    
DOI: 10.1155/2014/723868     Document Type: Article

References (28)

1. A. M. Di Bisceglie, "Hepatitis C and hepatocellular carcinoma," Hepatology, vol. 26, no. 3, supplement 1, pp. 34S-38S, 1997
2. J. W. Ward, "The epidemiology of chronic hepatitis C and onetime hepatitis C virus testing of persons born during 1945 to 1965 in the United States," Clinics in Liver Disease, vol. 17, no. 1, pp. 1-11, 2013
3. I. Saito, T. Miyamura, A. Ohbayashi et al., "Hepatitis C virus infection is associated with the development of hepatocellular carcinoma," Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 17, pp. 6547-6549, 1990
4. T. Kanda, F. Imazeki, andO. Yokosuka, "Newantiviral therapies for chronic hepatitis C," Hepatology International, vol. 4, no. 3, pp. 548-561, 2010
5. T. Kanda, O. Yokosuka, and M. Omata, "Treatment of hepatitis C virus infection in the future," Clinical and Translational Medicine, vol. 2, article 9, 2013
6. D. Ge, J. Fellay, A. J. Thompson et al., "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance," Nature, vol. 461, no. 7262, pp. 399-401, 2009
7. V. Suppiah, M. Moldovan, G. Ahlenstiel et al., "IL28B is associated with response to chronic hepatitisCinterferon and ribavirin therapy," Nature Genetics, vol. 41, no. 10, pp. 1100-1104, 2009
8. Y. Tanaka, N. Nishida, M. Sugiyama et al., "Genome-wide association of IL28B with response to pegylated interferon and ribavirin therapy for chronic hepatitis C," Nature Genetics, vol. 41, no. 10, pp. 1105-1109, 2009
9. T. Miyamura, T. Kanda, S. Nakamoto et al., "Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin," Viruses, vol. 4, no. 8, pp. 1264-1278, 2012
10. M. Sugiyama, Y. Tanaka, T. Wakita, M. Nakanishi, and M. Mizokami, "Genetic variation of the IL-28B promoter affecting gene expression," PLoS ONE, vol. 6, no. 10, Article ID e26620, 2011
11. T. Miyamura, T. Kanda, S. Nakamoto et al., "Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitisCvirus genotype 1-infected patients," PLoS ONE, vol. 6, no. 12, Article IDe28617, 2011
12. T. Kanda, X. Jiang, S. Nakamoto et al., "Different effects of three interferons L on toll-like receptor-related gene expression in HepG2 cells," Cytokine, vol. 64, no. 2, pp. 577-583, 2013
13. L. Prokunina-Olsson, B. Muchmore, W. Tang et al., "A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus," Nature Genetics, vol. 45, no. 2, pp. 164-171, 2013
14. S. Bibert, T. Roger, T. Calandra et al., "IL28Bexpressiondepends on a novel TT/-G polymorphism which improves HCV clearance prediction," Journal of ExperimentalMedicine, vol. 210, no. 6, pp. 1109-1116, 2013
15. Y. Nozawa, T. Umemura, Y. Katsuyama et al., "Genetic polymorphism in IFNL4 and response to pegylated interferon and ribavirin in Japanese chronic hepatitis C patients," Tissue Antigens, vol. 83, no. 1, pp. 45-48, 2014
16. S. Nakamoto, T. Kanda, F. Imazeki et al., "Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients," Scandinavian Journal of Gastroenterology, vol. 46, no. 7-8, pp. 955-961, 2011
17. H. Kumada, J. Toyota, T. Okanoue, K. Chayama, H. Tsubouchi, and N. Hayashi, "Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan," Journal of Hepatology, vol. 56, no. 1, pp. 78-84, 2012
18. T. Hara, N. Akuta, F. Suzuki et al., "Apilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C," Journal of Medical Virology, vol. 85, no. 10, pp. 1746-1753, 2013
19. T. Kanda, F. Imazeki, Y. Yonemitsu et al., "Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test," Journal of Viral Hepatitis, vol. 18, no. 7, pp. e292-e297, 2011
20. M. Omata, T. Kanda, M.-L. Yu et al., "APASL consensus statements and management algorithms for hepatitis C virus infection," Hepatology International, vol. 6, no. 2, pp. 409-435, 2012
21. Y. Nozawa, T. Umemura, Y. Katsuyama et al., "Genetic polymorphism in IFNL4 and response to pegylated interferon and ribavirin in Japanese chronic hepatitis C patients," Tissue Antigens, vol. 83, no. 1, pp. 45-48, 2014
22. H. Fujino, M. Imamura, Y. Nagaoki et al., "Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C," Journal of Gastroenterology, 2013
23. Y. Nagaoki, M. Imamura,Y. Kawakami et al., "Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C," Hepatology Research, 2014
24. A. F. Stättermayer, R. Strassl, A. Maieron et al., "Polymorphisms of interferon 4 and IL28B-effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C," Alimentary Pharmacology and Therapeutics, vol. 39, no. 1, pp. 104-111, 2014
25. L. M. Real, K. Neukam, R. Herrero et al., "IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians," PLoS ONE, vol. 9, no. 4,Article ID e95515, 2014
26. O. J. Hamming, E. Terczýnska-Dyla, G. Vieyres et al., "Interferon lambda 4 signals via the IFN receptor to regulate antiviral activity againstHCVand coronaviruses,"EMBOJournal, vol. 32, no. 23, pp. 3055-3065, 2013
27. O. Manuel, A. Wójtowicz, S. Bibert et al., "Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation," The Journal of Infectious Diseases, 2014
28. E. G. Meissner, D. Bon, L. Prokunina-Olsson et al., "IFNL4 G genotype is associated with slower viral clearance inHepatitisC, genotype-1 patients treated with sofosbuvir and ribavirin," Journal of Infectious Diseases, vol. 209, no. 11, pp. 1700-1704, 2014.